Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristina Pamfil has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Simona Rednic

    Department of Rheumatology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania

    9 shared publications
  • Laura Damian

    Rheumatology Department, Emergency County Clinical Hospital Cluj, 400347 Cluj-Napoca, Romania

    5 shared publications
  • Simona Rednic

    Department of Rheumatology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca; and Department of Rheumatology, Emergency Clinical County Hospital, Cluj-Napoca, Romania

    4 shared publications
  • Alexandra Roman

    Department of Periodontology, Applicative Periodontal Regeneration and Pediatrics Dental Medicine Research Center, Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Victor Babeș St., No. 15, 400012 Cluj-Napoca, Romania

    3 shared publications
  • Alina Bârdea

    Department of Periodontology, Applicative Periodontal Regeneration and Pediatrics Dental Medicine Research Center, Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Victor Babeș St., No. 15, 400012 Cluj-Napoca, Romania

    3 shared publications
  • Andrada Soancă

    Department of Periodontology, Applicative Periodontal Regeneration and Pediatrics Dental Medicine Research Center, Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca, Victor Babeș St., No. 15, 400012 Cluj-Napoca, Romania

    3 shared publications

Latest Publications

  • Open Access

    Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part II: MRI/CT Features, Prediction Models, and the Role of PET/CT—A Narrative Review

    by Oana Maria Vanta, Anamaria Marian, Manuela Lenghel, Linda Ghib, Sonia Irina Vlaicu, Larisa Rotaru, Ileana Nicoară, Simona Rednic, Cristina Pamfil

    Distinguishing tuberculous spondylodiscitis (TS) from pyogenic spondylodiscitis (PS) on imaging remains clinically important because the two entities differ in antimicrobial strategy, surgical timing, and the urgency of microbiological workup, yet no single imaging sign is pathognomonic for either diagnosis. When tissue confirmation is delayed, imaging becomes the primary tool that shifts pre-test probability and guides biopsy strategy—a role that is particularly critical in culture-negative disease, in antibiotic-exposed patients, and in settings with limited access to rapid mycobacterial diagnostics. This narrative review maps the imaging evidence most useful for routine TS-versus-PS differentiation, synthesizes recent prediction models and quantitative tools, and evaluates the adjunctive role of 18F-FDG PET/CT in biopsy-oriented decision-making. PubMed/MEDLINE was searched from inception to 31 March 2026 using pre-specified search terms across three concept blocks. This was a narrative review without formal pooling of quantitative estimates or prospective protocol registration. A secondary Scopus search identified no additional eligible records. Priority was given to comparative TS-versus-PS imaging cohorts, meta-analyses of MRI and CT features, prediction-model studies, and the recent radiomics and PET/CT literature; radiomics and deep-learning studies are appraised as a distinct evidence tier given their retrospective single-center derivation and predominantly internal-only validation. In total, 14 comparative TS-versus-PS imaging cohorts, three meta-analyses, and 14 prediction-model, quantitative-scoring, radiomics, or deep-learning studies formed the core evidence base. MRI yields the greatest differentiating information and is the recommended first-line modality. Features favoring TS include thoracic predominance, multilevel or non-contiguous involvement, relative early disc preservation, subligamentous spread, intraosseous abscesses, thin-walled paravertebral collections, and severe vertebral collapse with kyphotic deformity. Features favoring PS include lumbar predominance, early disc-endplate destruction, homogeneous inflammatory enhancement, facet-joint arthritis, and epidural phlegmon. CT adds osseous detail—including sequestra, subligamentous bone erosion, and paravertebral calcification—and remains the primary guidance modality for biopsy. Recent prediction models combining imaging and laboratory variables have shown high discriminative performance in derivation cohorts; however, most remain internally validated and locally calibrated. Pending external validation, none should be considered ready for unmodified clinical adoption, and they should therefore be used as probability modifiers rather than stand-alone diagnostic rules. 18F-FDG PET/CT is complementary rather than primary and is most useful when MRI is contraindicated or equivocal, in hardware-associated infection, and for whole-body staging in suspected disseminated tuberculosis. Non-infectious mimics and alternative infectious diagnoses should be considered when the imaging pattern is internally inconsistent or when standard cultures remain negative. Imaging findings should refine etiological probability and guide biopsy strategy, but should not replace tissue confirmation when tissue is feasible. Non-imaging evidence complementing this review is addressed in the companion manuscript, Part I.


  • Open Access

    Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part I—Epidemiology, Clinical Features, Laboratory Markers, and Tissue-Based Diagnosis

    by Anamaria Marian, Oana Maria Vanța, Valentin Danci, Larisa Rotaru, Maria-Magdalena Tămaș, Rodica Ungur, Simona Rednic, Cristina Pamfil

    Distinguishing tuberculous spondylodiscitis (TS) from pyogenic spondylodiscitis (PS) remains difficult when presentation is non-specific, blood cultures are negative, or initial biopsy is non-diagnostic. The two entities differ substantially in antimicrobial strategies, resistance testing requirements, public health interventions, and surgical thresholds, yet diagnostic delay is associated with neurological deficits, spinal instability, and permanent deformity. This narrative review maps the non-imaging evidence most useful for frontline differentiation between TS and PS across five domains: epidemiology and risk stratification, clinical presentation, laboratory markers, tissue acquisition and histopathology, and molecular diagnostics. PubMed/MEDLINE was searched from inception to 31 March 2026 using pre-specified Boolean search terms; a secondary Scopus search identified no additional eligible records. Following screening, approximately 90 records were included in this synthesis. Priority was given to comparative TS-versus-PS cohorts, biopsy-yield and culture-negative studies, pathology series, pediatric data, and recent molecular diagnostics literature. Epidemiological TB (tuberculosis) risk, longer symptom duration, constitutional symptoms, deformity, and a less intense acute-phase response increase the probability of TS, whereas healthcare exposure, bacteraemia, recent spinal procedures, and brisk neutrophilic inflammation favor PS. In stable patients, the highest-yield strategy is early blood cultures followed by image-guided biopsy with parallel tissue allocation for bacterial culture, mycobacterial studies, histopathology, and selected molecular assays. No single laboratory marker reliably distinguishes TS from PS without tissue confirmation. Per a 2023 systematic review and meta-analysis, image-guided percutaneous biopsy achieves microbiological confirmation in approximately one-third of cases. Histopathology demonstrating caseating granulomatous inflammation supports TS, although a substantial minority of confirmed cases lack classic features. Supported by cohort prospective data, Xpert MTB/RIF Ultra has the clearest first-line molecular role when TS is plausible and should be requested at the time of first biopsy rather than reserved for salvage testing; broader or targeted next-generation sequencing is best reserved for selected unresolved cases. Imaging differentiation is addressed in the companion manuscript, Part II.


  • Open Access

    Comparative Performance of SARC-F, SARC-CalF, SARC-F + EBM, and Ishii Score for Detecting Sarcopenia in Hospitalised Geriatric Patients

    by Ioana Daniela Rus, Vlad Ionuț Nechita, Lucreția Avram, Dana CrișAn, Cristina Pamfil, Laura Muntean, Elisabeta Ioana HirișCău, Valer Donca

    Background/Objectives: Sarcopenia is a progressive decline in skeletal muscle strength and mass, leading to decreased functionality, metabolic disorders, morbidity, and mortality. There are a number of sarcopenia screening tools, such as the SARC-F questionnaire (that includes noting strength, assistance with walking, ability to raise from the chair, climb stairs, and falls), with its augmented forms that have added calf circumference (SARC-CalF), BMI and age (SARC-F + EBM), and the Ishii score, which show variable performance across populations. However, these were developed and validated mostly in Asian cohorts. To evaluate the diagnostic accuracy of these tools for the European Working Group on Sarcopenia in Older People (EWGSOP2), as well as define sarcopenia in hospitalized East European older adults, with sex and obesity stratification. Methods: Sarcopenia was diagnosed using the EWGSOP2. ROC analyses with DeLong tests assessed SARC-F, SARC-CalF, SARC-F + EBM, and the Ishii score in 278 Romanian inpatients (probable sarcopenia n = 201/278, 72.3%; confirmed n = 77/278, 27.7%). Results: Probable sarcopenia was noted as good-excellent discrimination against across all tools (AUCs 0.764–0.812); confirmed sarcopenia was noted as SARC-CalF superior (AUC = 0.743), followed by SARC-F + EBM (0.697), the Ishii score as moderate (0.667), and SARC-F was limited (0.591; p < 0.001 vs. augmented). SARC-CalF optimal cut-offs varied significantly: 4–6 (probable) vs. ≥11 (confirmed). Sex-stratified outcomes had excellent probable detection in both sexes, and this was confirmed to be superior in men. The Ishii score thresholds were 152/244 vs. Asian ≥ 105/120. Obesity required higher cut-offs with high NPVs (77–100%), confirming rule-out utility and SARC-F + EBM performing the best, both in the obesity and sarcopenic obesity subgroups (AUCs 0.742, 0.964). Conclusions: Augmented SARC-F scores outperformed the original SARC-F for confirmed sarcopenia in multimorbid Europeans, with SARC-F CalF having the best performance overall. Population-specific (sex/obesity) data-driven thresholds are essential, especially for the Ishii score, as this first Romanian validation reveals limitations of Asian norms in European cohorts, thus advocating for European recalibration.


  • Open Access

    Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition

    by Cristina Pamfil, Mohamed Amin Taki, Elisabeta Candrea, Laura Damian, Maia Ioana Mihon, Diana Maria Margareta Moldovan, Simona Rednic

    Multicentric reticulohistiocytosis (MRH) is a rare systemic histiocytic disorder of uncertain etiology characterized by papulonodular cutaneous lesions and potentially destructive polyarthritis, with variable multisystem involvement. Owing to its low prevalence, evidence for optimal management remains limited, and treatment responses are heterogeneous. Emerging reports suggest that Janus kinase (JAK) inhibition may provide benefit in refractory disease. We report a 60-year-old woman with MRH presenting with papulonodular skin lesions, symmetric polyarthritis, constitutional symptoms, and interstitial lung disease (nonspecific interstitial pneumonia pattern) in the context of co-existing primary biliary cholangitis and no evidence of malignancy. Prior therapies (glucocorticoids, methotrexate, leflunomide) achieved suboptimal control. Upadacitinib, a selective JAK1 inhibitor, induced rapid and complete remission of cutaneous and articular disease with improvement of pulmonary involvement. Secondary weight gain and incident diabetes were managed with tirzepatide. This case adds to the limited literature supporting JAK inhibition as a targeted option for refractory MRH, including multisystem disease with pulmonary involvement. Systematic evaluation of efficacy, durability, and safety is warranted.


  • Open Access

    Comparative analysis of clinical characteristics of gout patients

    by Larisa Rotaru, Liliana Groppa, Eugeniu Russu, Svetlana Agachi, Larisa Spinei, Ludmila Negruța, Emil Ceban, Alexandru Corlateanu, Cristina Pamfil, Elena Sprincean, et al.

    Aim: Given the documented rise in the incidence and prevalence of gout over the past decade, this study aims to comparatively assess patients of different ages affected by gout in Romania and the Republic of Moldova. Material and methods: This cross-sectional observational study selectively included 490 patients with gout treated in the Republic of Moldova and Romania Results: In Romania, the study included 15 women (6.1%) and 230 men (93.9%) (mean age 52.24±1.18 years). The mean age of gout onset in these patients was 42.5±0.89 years. In the Republic of Moldova, 26 women (10.6%) and 219 men (89.4%) were included (mean age 49.2±1.05 years), with mean age of gout onset 47.6±0.52 years. Of Romanian patients, 29 (11.8%) had chronic intermittent gout with a primary attack, 42 (17.2%) had repeated attacks, and 174 (71%) had chronic tophaceous gout. In the Republic of Moldova, there were 11 (4.5%) patients with chronic intermittent gout and a primary attack, 28 (11.5%) patients with repeated attacks, and 206 (84%) patients with chronic tophaceous gout. Hereditary predisposition was observed in six (2.5%) patients in Romania and nine (3.8%) patients in the Republic of Moldova, most frequently among family members such as fathers, brothers, and uncles. Conclusions: The study reveals similarities and differences between patient’s from Romania and the Republic of Moldova in terms of prevalence, clinical evolution and hereditary predisposition of gout, underlining the need for a tailor-made approach in the management of this disease.

  • Open Access

    Pembrolizumab-induced fulminant triple M syndrome presenting with severe bradycardia

    by Maia Ioana Mihon, Cristina Pamfil, Ruxandra Beyer, Raluca Tomoaia, Anca Roxana Gherasim, Andrada Deac, Mihnea Tudor Zdrenghea, Virgil-Ioan Poltorac, Dana Marieta Fodor, Adrian Mariș, et al.

    Immune checkpoint inhibitors have markedly transformed cancer treatment paradigms but are frequently associated with immune-related adverse events (irAEs) affecting multiple organ systems. Among the rare and severe complications is the “triple M syndrome”, encompassing myositis, myocarditis, and myasthenic syndrome. We present the case of an 83-year-old male with stage IIc melanoma who received pembrolizumab as adjuvant therapy following surgical excision of the primary tumor and regional lymph nodes, with no evidence of neoplastic invasion. Approximately one month post-infusion, the patient experienced episodes of syncope, leading to the diagnosis of a second-degree atrioventricular block. Despite normal findings on echocardiography, the patient subsequently developed profound proximal muscle weakness, dysphonia, and dysphagia. Pembrolizumab was promptly discontinued, and the patient was initiated on high-dose intravenous methylprednisolone; however, his clinical course rapidly deteriorated, culminating in the necessity for palliative care due to progressive respiratory failure. This case underscores the potential for severe, life-threatening irAEs associated with pembrolizumab therapy, particularly in the form of triple M syndrome. Notably, the manifestations of myocarditis and myasthenia gravis (MG) within this context may occur in the absence of typical autoantibody markers, thereby complicating the diagnostic process and contributing to poor prognostic outcomes. This case highlights the imperative for heightened clinical vigilance and a proactive approach to monitoring for irAEs in patients receiving immune checkpoint inhibitors. Early recognition, coupled with the prompt initiation of therapeutic interventions, is paramount in mitigating morbidity and improving clinical outcomes in these critical scenarios.


  • Open Access

    Sex-Specific Differences in Cytokine Production Capacity in Patients with Gout Compared to Controls

    by Medeea Badii, Orsolya I. Gaal, Ioana Hotea, Valentin Nica, Andreea M. Mirea, Dragoş Mărginean, HINT Consortium, Cristina Pamfil, Simona Rednic, Radu A. Popp, et al.

    Gout, an inflammatory disease orchestrated by interleukin-1β activation and release, is more prevalent in men. The clinical profiles of patients with gout report differences by sex. This study aims to investigate sex-specific cytokine profiles in circulation and in stimulated peripheral blood mononuclear cells (PBMCs) of patients with gout and controls. Participants included in the gout group met the criteria of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). The control group included individuals with varying levels of serum urate and absence of gout. PBMCs were stimulated in vitro for 24 h with various TLR ligands. Cytokines were determined in culture supernatants and plasma. Plasma IL-1Ra and high-sensitivity C-reactive protein (hsCRP) were higher in men with gout compared to men without gout whereas no significant differences in circulating cytokines were observed in women. PBMCs of patients with gout showed higher cytokine production of IL-1β, IL-1Ra, and TNF-α following 24 h stimulation, predominantly observed in women. We identified sex-specific cytokine production in gout in response to in vitro stimulation. While men with gout had higher levels of circulating cytokines, stimulated PBMCs of women with gout show an enhanced capacity for cytokine production. These data may suggest potentially different regulatory mechanisms of inflammation in men and women with gout.


  • Open Access

    Insights into the Relationship between Periodontitis and Systemic Sclerosis Based on the New Periodontitis Classification (2018): A Cross-Sectional Study

    by Andreea Ciurea, Alina Stanomir, Petra Șurlin, Iulia Cristina Micu, Cristina Pamfil, Daniel Corneliu Leucuța, Simona Rednic, Giulio Rasperini, Andrada Soancă, Adrian Bogdan Țigu, et al.

    (1) Background: This study aimed to assess the periodontitis burden in systemic sclerosis patients and the possible association between them, and the degree to which some potential risk factors and two potential diagnostic biomarkers may account for this association. (2) Methods: This cross-sectional study included a test group (systemic sclerosis patients) and a control group (non-systemic sclerosis patients). Both groups benefited from medical, periodontal examination and saliva sampling to determine the salivary flow rate and two inflammatory biomarkers (calprotectin, psoriasin). A systemic sclerosis severity scale was established. (3) Results: In the studied groups, comparable periodontitis rates of 88.68% and 85.85%, respectively, were identified. There were no significant differences in the severity of periodontitis among different systemic sclerosis severity, or in the positivity for anti-centromere and anti-SCL70 antibodies. Musculoskeletal lesions were significantly more common in stage III/IV periodontitis (n = 33, 86.84%) than in those in stage I/II (n = 1, 100%, and n = 3, 37.5%, respectively) (p = 0.007). Comparable levels of the inflammatory mediators were displayed by the two groups. There were no significant differences in calprotectin and psoriasin levels between diffuse and limited forms of systemic sclerosis. (4) Conclusions: Within the limitations of the current study, no associations between systemic sclerosis and periodontitis, or between their risk factors, could be proven.


  • Open Access

    Current Perspectives on Periodontitis in Systemic Sclerosis: Associative Relationships, Pathogenic Links, and Best Practices

    by Andreea Ciurea, Nicolae Voicu Rednic, Andrada Soancă, Iulia Cristina Micu, Alina Stanomir, Diana Oneț, Petra Șurlin, Ileana Filipescu, Alexandra Roman, Ștefan Ioan Stratul, et al.

    Systemic sclerosis is a chronic, autoimmune, multisystemic disease characterized by aberrant extracellular matrix protein deposition and extreme progressive microvasculopathy. These processes lead to damage within the skin, lungs, or gastrointestinal tract, but also to facial changes with physiognomic and functional alterations, and dental and periodontal lesions. Orofacial manifestations are common in SSc but are frequently overshadowed by systemic complications. In clinical practice, oral manifestations of SSc are suboptimally addressed, while their management is not included in the general treatment recommendations. Periodontitis is associated with autoimmune-mediated systemic diseases, including systemic sclerosis. In periodontitis, the microbial subgingival biofilm induces host-mediated inflammation with subsequent tissue damage, periodontal attachment, and bone loss. When these diseases coexist, patients experience additive damage, increasing malnutrition, and morbidity. The present review discusses the links between SSc and periodontitis, and provides a clinical guide for preventive and therapeutical approaches in the management of these patients.